Epirubicin
- PDF / 169,383 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 23 Downloads / 133 Views
1 S
Diarrhoea and abdominal pain: 2 case reports In a single-center retrospective study of 98 patients, who received transarterial chemoembolisation (TACE) from January 2016 to June 2019, two patients [ages and sexes not stated] were described, who developed diarrhoea or abdominal pain during treatment with epirubicin for hypovascular hepatocellular carcinoma [times to reactions onsets not stated] The patients, who had hypovascular hepatocellular carcinoma, started receiving drug-eluting beads transarterial chemoembolisation (DEB-TACE) by dissolving 80mg epirubicin powder to 20 mg/mL, which was then mixed with a certain size of dehydrated beads for 30 min. Then, appropriate unspecified contrast agents were added before the beads infusion. Thereafter, the epirubicin drug-eluting beads were infused slowly into the hepatic arteries at a rate of 1 mL/min. Subsequently, one of the two patients developed grade 3 diarrhoea, and the other patient developed grade 3 abdominal pain. The patient’s symptoms gradually relieved with empirical treatment. Shi Q, et al. Drug-eluting beads versus lipiodol transarterial chemoembolization for the treatment of hypovascular hepatocellular carcinoma: A single-center retrospective 803497881 study. Cancer Management and Research 12: 5461-5468, Jan 2020. Available from: URL: http://doi.org/10.2147/CMAR.S255960
0114-9954/20/1818-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 22 Aug 2020 No. 1818
Data Loading...
